<DOC>
	<DOCNO>NCT01541943</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety HL-040XC patient essential hypertension hyperlipidemia</brief_summary>
	<brief_title>Efficacy Safety HL-040XC Essential Hypertension Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Aged 18 80 year History essential hypertension hyperlipidemia Able sign inform consent At screening , SBP ≥ 180mmHg DBP ≥ 110mmHg LDLC &gt; 250mg/dL TG ≥ 400mg/dL Has history hypersensitivity Angiotensin Ⅱ receptor blocker HMGCoA reductase inhibitor component drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Losartan</keyword>
	<keyword>Essential Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>